CTOs on the Move

Arrowhead Pharmaceuticals

www.arrowheadpharma.com

 
Arrowhead Pharmaceuticals is a clinical stage, Nasdaq listed (ticker ARWR) company developing medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, our therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Our RNAi-based therapeutics are at the leading edge of genetic-based therapy with the potential to bring life changing treatments for ...
  • Number of Employees: 100-250
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details
Scott Phillips
Director, Enterprise Systems and Compliance Profile

Funding

Arrowhead Pharmaceuticals raised $45M on 08/13/2016
Arrowhead Pharmaceuticals raised $45M on 08/16/2016

Similar Companies

Neuromed Pharmaceuticals

Neuromed Pharmaceuticals Ltd. is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Eversana

EVERSANA™ is a leading independent provider of global services to the life sciences industry. The company’s integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners, and payers. The company serves more than 670 organizations, including innovative start-ups and established pharmaceutical companies, to advance life sciences solutions for a healthier world.

Sol-Millennium Medical Group

SOL-MILLENNIUM is a vertically integrated global medical supply company with locations across the globe. We are one of the worlds largest manufacturers of needles, syringes, and blood collection devices with a comprehensive line of medical supplies fo...

BioBlast Pharma

BioBlast Pharma is a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. The Company is building a diverse portfolio of product candidates with the potential to address unmet medical needs for incurable diseases. The BioBlast platforms are based on deep understandings of the disease-causing biological processes, and potentially offer solutions for several diseases that share the same biological pathology.